Compugen (CGEN) Shares Outstanding (Diluted Average) (2010 - 2025)
Compugen recorded quarterly Shares Outstanding (Diluted Average) of $38.9 million in Q4 2013, up 7.23% quarter-over-quarter from $36.2 million in Q4 2012, and up 7.23% year-over-year from $36.2 million in Q4 2012.
Compugen's Shares Outstanding (Diluted Average) history runs 4 years deep, the most recent figure standing at $38.9 million for Q4 2013.
- In Q4 2013, Shares Outstanding (Diluted Average) rose 7.23% year-over-year to $38.9 million; the TTM figure through Dec 2013 stood at $38.9 million (up 7.23% YoY), while the FY2013 annual figure was $38.9 million, up 7.23% from the prior year.
- Shares Outstanding (Diluted Average) came in at $38.9 million for Q4 2013 at Compugen, up from $36.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $38.9 million in Q4 2013 to a low of $33.3 million in Q4 2010.
- A 4-year average of $35.7 million and a median of $35.3 million in 2011 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) climbed 2.98% in 2011 and grew 7.23% in 2013, its largest moves.
- Compugen's Shares Outstanding (Diluted Average) stood at $33.3 million in 2010, then advanced by 2.98% to $34.3 million in 2011, then increased by 5.75% to $36.2 million in 2012, then advanced by 7.23% to $38.9 million in 2013.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $38.9 million, $36.2 million, and $34.3 million for Q4 2013, Q4 2012, and Q4 2011 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Compugen | 234.03 Mn | 142.28 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 160.00 |
| Jun 30, 2024 | 100.00 |
| Jun 30, 2023 | 210.00 |
| Jun 30, 2022 | 220.00 |
| Jun 30, 2021 | 230.00 |
| Mar 31, 2019 | 60.02 Mn |
| Mar 31, 2018 | 51.98 Mn |
| Mar 31, 2017 | 51.13 Mn |
| Dec 31, 2015 | 50.53 Mn |
| Jun 30, 2015 | 50.41 Mn |
| Dec 31, 2014 | 50.14 Mn |
| Jun 30, 2014 | 49.80 Mn |
| Dec 31, 2013 | 42.74 Mn |
| Sep 30, 2013 | 39.15 Mn |
| Jun 30, 2013 | 39.14 Mn |
| Dec 31, 2012 | 36.25 Mn |
| Sep 30, 2012 | 36.80 Mn |
| Jun 30, 2012 | 130.00 |
| Dec 31, 2011 | 34.28 Mn |
| Sep 30, 2011 | 34.49 Mn |
| Dec 31, 2010 | 33.28 Mn |